Deciphera Pharmaceuticals Announces Initiation Of Phase 1 Cancer Trial For Altiratinib (DCC-2701) MET/TIE2/VEGFR/TRK Kinase Inhibitor For Solid Tumors
5/30/2014 9:36:50 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, a clinical stage biotechnology company focused on improved kinase inhibitor treatments for cancer, today announced the initiation of a Phase 1 clinical trial of its MET/TIE2/VEGFR2/TRK inhibitor altiratinib (DCC-2701). The Phase 1 trial will evaluate the safety, tolerability and initial efficacy of altiratinib in cancer patients with solid tumors. Altiratinib has been shown to exhibit high potency and selectivity for inhibiting MET, TIE2, VEGFR2, and TRK kinases in preclinical studies. A companion diagnostic assay will also be co-developed during the course of clinical studies.
Help employers find you! Check out all the jobs and post your resume.
comments powered by